Table 1 Participant demographics and comorbidities
Characteristics | All participants (N = 165) | COVID-19 present/overcome (n = 13) | COVID-19 absent (n = 152) | P value |
|---|---|---|---|---|
Age, years | 71.0 ± 15.8 | 72.1 ± 11.5 | 70.9 ± 16.2 | .97 |
Sex | ||||
Male | 93 (56.4) | 10 (76.9) | 83 (54.6) | .12 |
Female | 72 (43.6) | 3 (23.1) | 69 (45.4) | .12 |
History of possible exposure to Sars-CoV-2 | 11 (16.9) | 4 (30.8) | 7 (4.6) | .006 |
Smoker (former or current) | 41/142 (28.9) | 2/10 (20.0) | 39/132 (29.5) | .72 |
Body mass index, kg/m2 | 27.8 ± 8.1 | 28.9 ± 4.5 | 27.7 ± 8.5 | .26 |
Chronic pulmonary disease | 38 (23.0) | 5 (38.5) | 33 (21.7) | .18 |
Ischemic heart disease | 48 (29.1) | 5 (38.5) | 43 (28.9) | .53 |
Heart failure | 85 (51.5) | 7 (53.8) | 78 (51.3) | > .99 |
Cerebrovascular disease | 47 (28.5) | 1 (7.7) | 46 (30.3) | .11 |
Diabetes | 52/164 (31.7) | 4/12 (33.3) | 51 (33.6) | > .99 |
Currently uncontrolled | 22/164 (13.4) | 2/12 (16.7) | 20 (13.2) | .67 |
Well adjusted | 33/164 (20.1) | 2/12 (16.7) | 31 (20.4) | |
Malignancy | 45 (27.3) | 5 (38.5) | 39 (25.7) | .34 |
Current | 26 (15.8) | 3 (23.1) | 23 (15.1) | .68 |
Previous | 19 (11.5) | 3 (23.1) | 16 (10.5) | .68 |
Arterial hypertension | 131 (79.4) | 11 (84.6) | 120 (78.9) | > .99 |
Chronic renal failure | 52 (31.5) | 5 (38.5) | 47 (30.9) | .11 |
Immune-compromiseda | 71 (43.0) | 5 (38.5) | 66 (43.4) | .78 |
Chronic liver disease | 23 (13.9) | 2 (15.4) | 21 (13.8) | > .99 |